Segmentation of the bipolar disorder therapeutics market by drug class (mood stabilizers, anticonvulsants, atypical antipsychotics, antidepressant drugs, and anti-anxiety drugs), by mechanism of action (selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, benzodiazepines, beta blockers, and others), and by geography (the Americas, APAC, and EMEA). Top vendors include Allergan, AstraZeneca, BMS, Eli Lilly, GSK, and Janssen Pharmaceuticals.
Technavio has released its new market research report, global bipolar disorder therapeutics market, which is expected to grow at a CAGR of 2% between 2015 and 2019. Atypical antipsychotics, mood stabilizers and antidepressants are being widely used in the treatment of the disorder. Americas dominates the global market for bipolar disorder therapeutics, accounting for 65% of the overall market share. The primary reason for this region’s growth is expected launches of various late stage pipeline molecules in the forecast period.
“Mood stabilizers are the drugs that are highly recommended and used for reducing manic symptoms in bipolar disorder as these drugs help in stabilizing the symptoms observed in the individuals and also help in treating the suicidal tendencies. Selective serotonin reuptake inhibitors are preferred as the first-line of therapy for the treatment of depression in bipolar disorder as these medications are considered safe and effective. Selective serotonin reuptake inhibitors act on neurotransmitters that transmit messages between brain cells,” says Brahadeesh Chandrasekaran, Lead Analyst, Healthcare & Lifesciences, Technavio Research.
The prevalence of bipolar disorder has increased considerably, which can be attributed to the increased awareness about the disease, thus leading to its easy recognition and diagnosis. It is considered to be the sixth leading cause of disability in the world. Thus, the surge in the number of patients suffering from bipolar disorder is expected to be one of the main driving forces for the growth of the global bipolar disorder therapeutics market during the forecast period.
The key vendors in the global bipolar disorder therapeutics market include Allergan, AstraZeneca, BMS, Eli Lilly, GSK, and Janssen Pharmaceuticals. Currently, the market is growing at a slow pace and the unavailability of effective treatment options is leading to unmet medical need in the market. Therefore, there is a huge growth opportunity for companies that are manufacturing and marketing drugs, which can effectively treat bipolar disorder, at the same time exhibiting a high safety and efficacy profile.
A more detailed analysis is available in the Technavio report, Global Bipolar Disorder Therapeutics Market 2015-2019.
We can customize this reports by other regions and specific segments upon request.
Other related reports:
